Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis’ Cosentyx available on NHS in Scotland

January 19, 2021
Manufacturing and Production Novartis

Novartis has announced that Cosentyx (secukinumab) 150mg is available in Scotland on the NHS, licensed for adults with active non-radiographic …

News

Novartis’ ligelizumab granted FDA Breakthrough Therapy Designation

January 14, 2021
FDA, Novartis

The FDA has granted Novartis’ ligelizumab Breakthrough Therapy Designation for the treatment of chronic spontaneous urticaria (CSU) in patients who …

News
novartis_outside_1

Novartis and BeiGene join forces to develop cancer drug tislelizumab

January 12, 2021
Manufacturing and Production BeiGene, Cancer, Novartis

Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …

News
novartis_outside_1

Novartis acquires Cadent Therapeutics in potential $770 million deal

December 17, 2020
Sales and Marketing Cadent, Novartis, acquisition

Novartis has sealed an agreement with Cadent Therapeutics to acquire the firm in a deal worth up to $770 million, …

News
nice_new_london_office_internal_3_web

NICE recommends Novartis’ Beovu for wet age-related macular degeneration

December 16, 2020
Research and Development NICE, Novartis, wet AMD Beovu

NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …

News
dw-anzcxqaqavhl

FDA panel backs Novartis’ Entresto for different form of heart disease

December 16, 2020
Research and Development FDA, Novartis, heart failure

Novartis’ heart failure drug Entresto has received recommendation from the FDA’s Cardiovascular and Renal Drugs Advisory Committee for use in …

News
shutterstock_95714119

Novartis and Incyte’s ruxolitinib fails to show benefit in COVID-19 at Phase 3

December 14, 2020
Research and Development, Sales and Marketing COVID-19, Incyte, Novartis

Novartis has unveiled that its JAK 1/2 tyrosine kinase inhibitor ruxolitinib fell short of its main efficacy goal in the …

News

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …

News

Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer

December 9, 2020
Research and Development Kisqali, Novartis, breast cancer

Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …

News
kymriah

Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma

December 7, 2020
Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis

Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …

News
shutterstock_38078521

Jakafi outperforms best available therapy in steroid-refractory/dependent chronic graft-versus-host disease

December 7, 2020
Research and Development, Sales and Marketing Incyte, Jakafi, Novartis

The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …

News

Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis

October 15, 2020
Sales and Marketing Mayzent, Novartis, Scotland

Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …

News
novartis_outside_1

Novartis unveils strong Phase 3 efficacy for one-time therapy Zolgensma in paediatric spinal muscular atrophy

October 1, 2020
Research and Development Novartis, Zolgensma, spinal muscular atrophy

Novartis has lifted the curtain on new Phase 3 data from an ongoing trial of 33 participants on the efficacy …

News
shutterstock_159488225

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …

News
novartis_outside_1

Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data

September 17, 2020
Research and Development Novartis, Tafinlar, mekinist, melanoma

Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025